CRON vs NAGE
Cronos Group Inc. and Niagen Bioscience, Inc., side by side — 9 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CRON | NAGE |
|---|---|---|
| Revenue | $146.6M | $129.4M |
| Net income | $-9.4M | $17.4M |
| Gross margin | 42.8% | 64.3% |
| Net margin | −6.4% | 13.4% |
| Return on equity | −0.9% | 28.3% |
| Diluted EPS | −$0.02 | $0.20 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $149,000 | $-21.2M |
| Equity | $1.1B | $76.5M |
| Net debt / equity | — | — |
| Current ratio | 19.59× | 4.86× |
| Revenue CAGR 5y | 25.7% | 16.9% |
| Profit CAGR 5y | — | — |
CRON and NAGE book revenue within 15% of each other, and CRON closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
9 years side by side
| Fiscal year | CRON | NAGE |
|---|---|---|
| FY2025 | $146.6M | $129.4M |
| FY2024 | $117.6M | $99.6M |
| FY2023 | $87.2M | $83.6M |
| FY2022 | $86.7M | $72.0M |
| FY2021 | $64.6M | $67.4M |
| FY2020 | $46.7M | $59.3M |
| FY2019 | $23.8M | $46.3M |
| FY2018 | $12.1M | $31.6M |
| FY2017 | $3.1M | $21.2M |
Net income by year
Bottom line
| Fiscal year | CRON | NAGE |
|---|---|---|
| FY2025 | $-9.4M | $17.4M |
| FY2024 | $41.1M | $8.6M |
| FY2023 | $-74.0M | $-4.9M |
| FY2022 | $-168.7M | $-16.5M |
| FY2021 | $-396.1M | $-27.1M |
| FY2020 | $-73.1M | $-19.9M |
| FY2019 | $1.2B | $-32.1M |
| FY2018 | $-21.6M | $-33.3M |
| FY2017 | $-1.5M | $-11.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry